These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19733394)

  • 1. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
    Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K
    Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Wang Z; Zhou J; Lu X; Gong Z; Le XC
    Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic-induced APL differentiation in cerebrospinal fluid.
    Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
    Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
    Yoshino Y; Yuan B; Miyashita SI; Iriyama N; Horikoshi A; Shikino O; Toyoda H; Kaise T
    Anal Bioanal Chem; 2009 Jan; 393(2):689-97. PubMed ID: 19009285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia.
    Jin Z; Ran M; Man Z
    Haematologica; 2007 Sep; 92(9):e82-4. PubMed ID: 17768137
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
    Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
    Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical artefacts in the speciation of arsenic in clinical samples.
    Slejkovec Z; Falnoga I; Goessler W; van Elteren JT; Raml R; Podgornik H; Cernelc P
    Anal Chim Acta; 2008 Jan; 607(1):83-91. PubMed ID: 18155413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
    Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
    Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
    Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
    Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
    Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
    Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
    Zhao W; Wang X; Guo W; Qu B; Wang H; Shen Z; Chen Z; Wang Z
    Chin Med J (Engl); 2000 Mar; 113(3):236-40. PubMed ID: 11775254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T; Westervelt P; Hess JL
    Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
    Kumana CR; Au WY; Lee NS; Kou M; Mak RW; Lam CW; Kwong YL
    Eur J Clin Pharmacol; 2002 Nov; 58(8):521-6. PubMed ID: 12451429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
    Au WY; Tam S; Fong BM; Kwong YL
    Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490
    [No Abstract]   [Full Text] [Related]  

  • 18. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.
    Iriyama N; Yoshino Y; Yuan B; Horikoshi A; Hirabayashi Y; Hatta Y; Toyoda H; Takeuchi J
    J Hematol Oncol; 2012 Jan; 5():1. PubMed ID: 22272800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
    Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia.
    George B; Mathews L; Balasubramanian P; Shaji RV; Srivastava A; Chandy M
    Haematologica; 2004 Oct; 89(10):1266-7. PubMed ID: 15477216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.